Toronto, Ontario – TheNewswire - June 17, 2025 – Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) is pleased to announce that it has entered into an advisory agreement with Fournel Advisory (“Fournel”) to provide the Company with financial advisory, business development and M&A services for one year to accelerate the commercialization of Ventripoint’s AI-powered, heart-scanning technology. Under the terms of the agreement the Company shall pay a cash fee and provide Fournel an option to purchase 265,000 common shares at the market price on June 11, 2025 of $0.11, subject to TSX Venture Exchange approval.

 

Strategic Advisory

 

Fournel Advisory is a Paris-based consulting firm dedicated to supporting entrepreneurs and business leaders across Small and Mid-Cap markets. Since 2013, Fournel has specialized in M&A advisory, fundraising, and special situations, both in France and internationally. With a strong focus on the Healthcare and Life Sciences sectors, it brings tailored, high-impact advice to clients at every stage of their growth. It is supported by the "Fournel Advisory Life Sciences" (FALS) Scientific Committee - referred to as its KOL network - comprising leading figures from academia, biotechnology, life sciences, and finance worldwide. This unique resource allows Fournel to identify new trends, provide strategic insights into value creation, and support critical fundraising documentation.

 

Fournel Advisory has completed more than 50 transactions since its inception and currently supports around 30 active mandates, ranging from biotech and medtech to pharma and medical devices. It is stage-agnostic, helping startups and growth companies alike, from early development through late-stage expansion. 70% of Fournel’s client base and investor relationships are international, especially across North America (U.S. and Canada) and Europe.

 

Founded by Pierre-Jean Esmieu Fournel, a former HEC graduate and Investment Banker at Société Générale (New York, South Africa, UK), and later CFO and VP of Business Development at Ethypharm, where he led a $135M fundraising in a turnaround situation, Fournel Advisory was born out of firsthand experience in the challenges - and the promise - of the biotech and pharma worlds. Fournel is passionate about enabling pioneering companies to achieve their ambitions by providing financial expertise, strategic advice, and access to a global network of investors and partners.

 

“Ventripoint is excited by the opportunity to work with the Fournel Advisory team” stated Ventripoint President and CEO Hugh MacNaught. “Their experience in the Healthcare sector and extensive network will be invaluable in accelerating Ventripoint’s growth and supporting the true value of the Company.”

 

Commenting on the agreement, Pierre-Jean Esmieu Fournel said: “We are delighted to partner with Ventripoint, a company at the intersection of AI and cardiac imaging, whose technology has the potential to reshape cardiovascular diagnostics. At Fournel Advisory, we strongly believe in the power of healthcare innovation, and we are committed to leveraging our global network and financial expertise to support Ventripoint’s growth and long-term success.”

 

With its proprietary VMS+™ platform, Ventripoint is revolutionizing cardiac diagnostics by delivering a powerful AI-driven solution that enhances echocardiography and serves as an affordable and more accessible alternative to traditional MRI scans. Following recent regulatory milestones, Ventripoint is now primed to expand its presence in key markets and drive widespread adoption.

 

For further information, please contact:

Hugh MacNaught

hmacnaught@ventripoint.com

(604) 671-4201

 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

 

About Ventripoint Diagnostics Ltd.

 

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

  

Forward Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends'' and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.

Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to several factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether because of new information, future events or otherwise, unless so required by applicable securities laws.